The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Director

27 Jan 2014 14:46

RNS Number : 6069Y
Akers Biosciences, Inc.
27 January 2014
 



 

27 January 2014

 

Akers Biosciences, Inc.

("ABI" or the "Company")

 

Appointment of Non-Executive Director

 

Akers Biosciences, Inc (AIM: AKR, NASDAQ:AKER), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that Brandon Knox will be appointed to the board as a Non-Executive Director effective immediately.

 

Brandon Thomas Knox, aged 34, has been a wealth adviser at Raymond James in Philadelphia since December 2012. His practice focuses on investment and estate solutions for high net worth families and individuals as well as public and private institutions both locally and nationally. Prior to joining Raymond James, Mr. Knox was a wealth adviser at Morgan Stanley from July 2008 to October 2012. Between 2006 and 2008, Mr. Knox served as Deputy Finance Director for the Philadelphia mayoral campaign of his father, Thomas Knox. In this role he concentrated on the organisation and management of campaign fundraising efforts as well as the planning and execution of campaign events and off-site functions.

 

Mr. Knox sits on the Board of Directors of The Committee of Seventy and is a member of the Drexel University Presidents Leadership Council and the Archdiocese of Philadelphia's OSD Advisory Council. Mr. Knox holds a B.S. in Economics from West Chester University and an M.B.A. in Financial Management from Drexel University's LeBow College of Business. 

 

Mr Knox has not held any other previous directorships in the five years preceding his appointment at ABI.

 

Commenting on the appointment, Thomas A. Nicolette, Chief Executive Officer said:

 

"I am delighted to welcome Brandon to the Board of ABI. We believe that Brandon's vast experience with corporate finance and financial management will make him an ideal board member helping the Company to manage its finances as it continues its growth."

 

Mr Knox is currently beneficially interested in 48,076 common shares of no par value representing 0.98% of the issued share capital of the Company.

 

There is no further information required relating to Brandon Thomas Knox to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

 

- ends -

 

Enquiries:

Thomas A. Nicolette, President and CEO

Tel. +1 856 848 8698

Antony Legge / James Thomas

Daniel Stewart (Nomad and Broker)

Ben Simons

Vigo Communications

 

Tel. +44 (0)20 7776 6550

 

Tel. +44 (0) 20 7016 9574

 

 

About Akers Biosciences, Inc.

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLFSSLEIDFIS
Date   Source Headline
4th Jun 20147:00 amRNSDistribution Agreement Signed
16th May 20147:00 amRNSAgreement to Market Rapid Tests in India
14th May 201412:00 pmRNSFirst Quarter Results
7th May 20147:00 amRNSInternational Distribution Agreement
30th Apr 20147:01 amRNSClinical Trials for PIFA PLUSS Chlamydia Assay
28th Mar 201411:00 amRNSFinal Results
27th Mar 201411:00 amRNSSenior Managerial Appointment
12th Mar 20145:12 pmRNSDirectorate Change
11th Mar 20144:30 pmRNSNASDAQ IPO Update
11th Mar 20144:29 pmRNSHolding(s) in Company
31st Jan 20145:30 pmRNSHolding(s) in Company
31st Jan 20147:00 amRNSDirector/PDMR Shareholding
31st Jan 20147:00 amRNSTotal Voting Rights
27th Jan 20142:46 pmRNSAppointment of Non-Executive Director
24th Jan 20147:30 amRNSRestoration - Akers Biosciences, Inc
23rd Jan 20146:10 pmRNSPricing of Offering & Recommencement of Trading
23rd Jan 20147:30 amRNSSuspension - Akers Biosciences, Inc.
23rd Jan 20147:30 amRNSTemporary Suspension
7th Jan 20145:27 pmRNSCorrection: SEC filings available on website
7th Jan 20144:54 pmRNSSEC filings available on Company's web site
2nd Jan 201410:37 amRNSHolding(s) in Company
31st Dec 201312:34 pmRNSCorrection: Total Voting Rights
31st Dec 20138:00 amRNSTotal Voting Rights
30th Dec 20137:00 amRNSIssue of Equity
23rd Dec 20137:00 amRNSPlacing of Shares
9th Dec 20137:00 amRNSProposed NASDAQ Listing
6th Dec 20137:00 amRNSDirector Dealing
5th Dec 20139:51 amRNSHolding(s) in Company
29th Nov 20134:00 pmRNSTotal Voting Rights
18th Nov 20137:00 amRNSShare Capital Consolidation
15th Nov 20132:37 pmRNSUnaudited results for nine months ended 30.09.2013
7th Nov 20134:55 pmRNSHolding(s) in Company
23rd Oct 20133:09 pmRNSHolding(s) in Company
17th Oct 20132:09 pmRNSHolding(s) in Company
17th Oct 20131:54 pmRNSHolding(s) in Company
22nd Aug 20137:00 amRNSInterim Results for Six Months Ended 30 June 2013
15th Aug 20138:55 amRNSHolding(s) in Company
8th Aug 20137:00 amRNSProposed NASDAQ Listing
23rd Jul 20137:00 amRNSDirector's Dealing
19th Jul 20137:00 amRNSTrading Statement
10th Jul 20139:51 amRNSHolding(s) in Company
1st Jul 20139:41 amRNSAppointment of Non-Executive Directors
26th Jun 20137:00 amRNSPreliminary Results for Year End 31 December 2012
14th Jun 201312:25 pmRNSHolding(s) in Company
13th Jun 20131:24 pmRNSExtension of Agreement & $1.6m Subscription
10th Apr 20137:00 amRNSTrading Update
27th Feb 20138:39 amRNSFinal Award of NF Mark
19th Feb 20137:00 amRNSTrading Update
20th Dec 20125:35 pmRNSResult of AGM
11th Dec 20127:00 amRNS3.5m unit Order for Breath Alcohol tubes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.